However, there are no drugs that specifically block MAPK4 that could be tested to reduce tumor growth. Instead, Yang and his colleagues explored an alternative approach.
We showed that blocking both AKT and PDK1 effectively repressed MAPK4-induced cancer cell growth, suggesting a potential therapeutic strategy to treat MAPK4-dependent cancers, such as a subset of TNBC, prostate and lung cancer.
“In this study we have not only advanced our understanding of the molecular mechanism underlying the tumor-promoting activity of MAPK4, we also have found a potential novel therapeutic approach for human cancers,” Yang said.
Comments are closed.